RNA binding motif protein 17 (RBM17)

RNA binding motif protein 17 (RBM17), also known as Splicing factor 45 (SPF45), is an RNA-binding protein involved in pre-mRNA splicing as part of the spliceosome complex and promotes utilization of the 3' AG at the exon/intron border during the second catalytic step of mRNA splicing[3][8]. RBM17 regulates alternative splicing, including the utilization of cryptic splice sites. It binds single-stranded RNA and works within ribonucleoprotein complexes, impacting alternative splicing and gene expression post-transcriptionally[3][7][8]. The family of RNA-binding motif proteins, including RBM17, is broadly implicated in RNA processing, editing, and polyadenylation, with emerging evidence linking dysregulation of these proteins to cancer and other diseases[1][2][3]. If further details—particularly about interacting drugs, mechanisms of action, biomarkers, or safety concerns—are needed for clinical or drug development purposes, more specialized pharmacological databases or recent literature would be necessary, as current sources do not indicate specific direct-acting drugs or safety liabilities for RBM17 in the clinic.

Other names

Splicing factor 45SPF45MGC1443945 kDa-splicing factorsplicing factor 45kDa